Welcome to the Bioasis Technologies Hub On AGORACOM

Free
Message: Aducanumab and the amyloid beta hypothesis is not dead yet!

,,,agreed,,,,,BTI shareholders should be very excited about the possibility with an Xb3 + aducanumab conjugate,,,,,,!!!

,,,,,just here waiting for a news catalyst to catapult us out of this share price level,,,,,,cuz,,,,,,,,with a $20 billion combined increase in market caps on both BIIB and their partner ESALY in one trading session today ,,well,,,it should make deep pocket traders jaw drop,,,,,,,,,,,

Share
New Message
Please login to post a reply